THERACRYF PLC (TCF) — Final Results for the year ended 31 March 2026

Investor webinar replay

Replay transcript excerpt

Speaker 1: Good afternoon and welcome to the Theracreef PLC investor presentation. Speaker 1: Throughout this recorded presentation, investors will be in a snowy mode. Questions are encouraged and could be submitted at any time via the Q&A tab situated on the right-hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself, however, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll and I'd like to hand you over to Hugh Jones, CEO. Good afternoon, sir. Speaker 2: Thanks Lillian, good afternoon everybody. Thanks for attending our slightly delayed final results to the 31st of March 2026 and I think the reasons for that are now obvious with me here on the webinar, Dr Alastair Smith, our Chair, and Tony Heinonen, our Chief Financial Officer and together we'll take you through the results of the 31st of March and the equally busy period in the post period. Speaker 2: We're aim listed, of course, and a private company, so the usual disclaimers apply. Speaker 2: To start then, I'll hand over to Alistair to bring you up to speed with who we are and what we do. Speaker 3: Great, thanks Jim. Afternoon everyone. Well as I'm sure you know Theracriff is focused on improving the lives of individuals with Speaker 3: neuropsychiatric Speaker 3: disorders and The way in which biotechs Speaker 3: generate returns for shareholders relies on building strong data sets around Speaker 3: commercially valuable drug molecules to deliver licensing deals and the best value is generated Speaker 3: from more advanced assets, particularly clinical stage assets and Speaker 3...